Photo of Brad McGregor,  MD

Brad McGregor, MD

Dana-Farber Cancer Institute

Dana-Farber Cancer Institute
Phone: (617) 632-6328


bradley_mcgregor@dfci.harvard.edu

Brad McGregor, MD

Dana-Farber Cancer Institute

EDUCATIONAL TITLES

  • Instructor, Medicine, Harvard Medical School
  • Clinical Director, Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute
  • GU Network Liason, CSO Cabinet, Dana-Farber Cancer Institute

DF/HCC PROGRAM AFFILIATION

Research Abstract

I serve as the clinic director for the Lank Center for Genitourinary Oncology at Dana Farber Cancer Institute. My practice encompasses medical oncologic care for all genitourinary malignancies to include kidney, bladder, prostate, testicular and rare tumors.

From a research perspective, I am an active participant in clinical trials. In collaboration with others, we are exploring the role of combination immunotherapy in rare genitourinary cancers (non-traditional bladder and prostate cancer, adrenocortical cancer, treatment refractory testicular cancer, penile cancer) In addition, I am leading trials exploring novel combinations of immunotherapies with other agents in a variety of tumor types while also exploring the role of anti-body drug conjugates in heavily treated cases of kidney and bladder cancer.

I also am involved in efforts to better elucidate prognostic and predictive markers exploring different mutations on the tumor as well as blood based markers that may assist in future treatment decisions.

Publications

Powered by Harvard Catalyst
  • Pal SK, Sonpavde G, Agarwal N, Vogelzang NJ, Srinivas S, Haas NB, Signoretti S, McGregor BA, Jones J, Lanman RB, Banks KC, Choueiri TK. Evolution of Circulating Tumor DNA Profile from First-line to Subsequent Therapy in Metastatic Renal Cell Carcinoma. Eur Urol 2017. PubMed
  • McGregor BA, Brown AW, Osswald MB, Savona MR. The use of higher dose clofarabine in adults with relapsed acute lymphoblastic leukemia. Am J Hematol 2009; 84:228-30. PubMed